CIS-2-(4-{2-[(ETHOXYCARBONYL)AMINO]ETHOXY}BENZYL)CYCLOHEXYL(3ALPHA,5BETA,7ALPHA,12ALPHA)-3,7,12-TRIS(FORMYLOXY)CHOLAN-24-OATE


Source	Gaulton A, Kale N, van Westen GJ, Bellis LJ, Bento AP, Davies M, Hersey A, Papadatos G, Forster M, Wege P, Overington JP. A large-scale crop protection bioassay data set. Sci Data. 2015 Jul 7;2:150032. Read more ...


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70

Structure


InChI Key	MKFQFFIZIKHHDV-QHOHUYJUSA-N
Smiles	CCOC(=O)NCCOc1ccc(C[C@@H]2CCCC[C@@H]2OC(=O)CC[C@@H](C)[C@H]3CC[C@H]4[C@@H]5[C@@H](C[C@@H]6C[C@@H](CC[C@]6(C)[C@H]5C[C@H](OC=O)[C@]34C)OC=O)OC=O)cc1
InChI	InChI=1S/C45H65NO11/c1-5-52-43(51)46-20-21-53-33-13-11-30(12-14-33)22-31-8-6-7-9-38(31)57-41(50)17-10-29(2)35-15-16-36-42-37(25-40(56-28-49)45(35,36)4)44(3)19-18-34(54-26-47)23-32(44)24-39(42)55-27-48/h11-14,26-29,31-32,34-40,42H,5-10,15-25H2,1-4H3,(H,46,51)/t29-,31+,32+,34-,35-,36+,37+,38+,39-,40+,42+,44+,45-/m1/s1

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C45H65NO11
Molecular Weight	796.0
AlogP	7.87
Hydrogen Bond Acceptor	11.0
Hydrogen Bond Donor	1.0
Number of Rotational Bond	20.0
Polar Surface Area	152.76
Molecular species	NEUTRAL
Aromatic Rings	1.0
Heavy Atoms	57.0

Assay Description	Organism	Bioactivity	Reference
Inhibition of metamorphosis in freshly molted Pyrrhocoris apterus (red firebug) fourth-instar nymph assessed as compound dose per individual causing reduction in metamorphosis by oral drinking assay	Pyrrhocoris apterus	0.051 ug
Inhibition of metamorphosis in freshly molted Pyrrhocoris apterus (red firebug) fifth-instar nymph assessed as compound dose per individual causing reduction in metamorphosis by topical screening test	Pyrrhocoris apterus	0.094 ug

Cross References

Resources	Reference
ChEMBL	CHEMBL2252507
PubChem	76326382

CONTENTS


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).